research use only

Pantoprazole Proton Pump inhibitor

Name: Pantoprazole
Brand: Selleck Chemicals
SKU: S2105
Availability: InStock
Rating: 5 (5 reviews)

Cat.No.S2105

Pantoprazole (SKF96022, BY-1023) is a proton pump inhibitor drug that inhibits gastric acid secretion. It works on gastric parietal cells to irreversibly inhibit (H+/K+)-ATPase function and suppress the production of gastric acid.

Chemical Structure

Molecular Weight: 383.37

Jump to

Quality Control

Batch: S210501 DMSO]76 mg/mL]false]Ethanol]76 mg/mL]false]Water]Insoluble]false Purity: 99.94%

Cited in Nature Medicine for its top-tier quality
COA
NMR
SDS
Datasheet

99.94

Related Targets	CFTR CRM1 CD markers AChR Calcium Channel Sodium Channel Potassium Channel GABA Receptor TRP Channel ATPase
Other Proton Pump Inhibitors	Bafilomycin A1 (Baf-A1) Ilaprazole sodium Ilaprazole Tenatoprazole Revaprazan Hydrochloride PF-3716556 Ufiprazole

Solubility

In vitro
Batch:

DMSO : 76 mg/mL (198.24 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : 76 mg/mL

Water : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

% Tween 80

% ddH₂O

% DMSO

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight	383.37	Formula	C₁₆H₁₅F₂N₃O₄S	Storage (From the date of receipt)	3 years-20°Cpowder
CAS No.	102625-70-7	Download SDF		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	SKFSKF96022, BY-1023			Smiles	COC1=C(C(=NC=C1)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC(F)F)OC

Mechanism of Action

Targets/IC₅₀/Ki	(H+/K+)-ATPase Proton pump
In vitro	PPZ(Pantoprazole) inhibits the proliferation of tumor cells, induces apoptosis and downregulates the expression of PKM2, which contributes to the current understanding of the functional association between PPZ and PKM2(The human M2 isoform of pyruvate kinase). Ex vivo studies showed that pantoprazole inhibited TOPK activities in JB6 Cl41 cells and HCT 116 colorectal cancer cells. Moreover, knockdown of TOPK in HCT 116 cells decreased their sensitivities to pantoprazole.
In vivo	i.p. injection of pantoprazole in HCT 116 colon tumor-bearing mice effectively suppresses cancer growth. The TOPK downstream signaling molecule phospho-histone H3 in tumor tissues is also decreased after pantoprazole treatment. At higher infusion rates, pantoprazole is able to induce negative hemodynamic responses, in particular, in the setting of heart failure. These effects can lead to significant impairment of cardiac function. Also, pantoprazole delays fracture healing by affecting both bone formation and bone remodeling.
References	[1] https://pubmed.ncbi.nlm.nih.gov/19938880/ [2] https://pubmed.ncbi.nlm.nih.gov/26870273/ [3] https://pubmed.ncbi.nlm.nih.gov/26967058/ [4] https://pubmed.ncbi.nlm.nih.gov/25529757/ [5] https://pubmed.ncbi.nlm.nih.gov/22527206/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04248335	Recruiting	Pediatric Obesity\|NAFLD\|GERD	Children''s Mercy Hospital Kansas City	July 3 2018	Phase 4
NCT02401035	Terminated	Gastroesophageal Reflux Disease	Pfizer	May 9 2017	Phase 4
NCT02274961	Unknown status	Non Erosive Reflux Disease	Ahn-Gook Pharmaceuticals Co.Ltd	October 2014	Phase 3
NCT02186652	Completed	Gastroesophageal Reflux Disease	Phillip Brian Smith\|The Emmes Company LLC\|Duke University	June 4 2014	Phase 1
NCT01710462	Withdrawn	Gastroesophageal Reflux Disease	Eurofarma Laboratorios S.A.	August 2013	Phase 3

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):